Cancer Type;T-Stage;N-Stage;M-Stage;Stage;Age;Treatment Plan
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1a;N0;M0;IA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1a (Tumor ≤1 cm in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. Tumor Surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1a N0 M0 corresponds to Stage IA.  Evidence-Based Treatment Plan:

Primary Treatment – Surgery:

Lobectomy is the preferred surgical approach due to its higher curative potential.
Segmentectomy or wedge resection may be considered in:
Patients with small tumors.
Individuals with limited pulmonary reserve or other comorbidities precluding lobectomy.
In all cases, systematic lymph node dissection or sampling should be performed to assess nodal involvement.
Non-Surgical Candidates:

If surgery is contraindicated due to poor cardiopulmonary status or serious comorbid conditions, stereotactic body radiation therapy (SBRT) is the recommended curative alternative.
Other external beam radiation therapies or ablation techniques may be considered when SBRT is not suitable.
Adjuvant Therapy:

Routine adjuvant chemotherapy or immunotherapy is not recommended for patients with completely resected Stage IA NSCLC, as no survival benefit has been consistently demonstrated.
In cases of positive surgical margins, re-resection or adjuvant radiotherapy may be considered.
Participation in clinical trials may be offered to patients at high risk for recurrence.
Follow-up and Surveillance:

Patients should undergo regular follow-up with imaging (e.g., chest CT) and clinical evaluation:
Every 3 months for the first 2 years.
Every 6 months for the next 3 years.
Annually after 5 years.
Smoking cessation should be strongly encouraged, as it improves survival and reduces the risk of recurrence or second primary lung cancers.
Late-onset and long-term side effects of treatment must be monitored.
Summary:
Surgical resection, particularly lobectomy, remains the cornerstone of curative therapy for Stage IA NSCLC. SBRT is an effective non-surgical option for inoperable patients. Routine adjuvant therapy is not recommended unless high-risk features or incomplete resection are present. Close surveillance and smoking cessation are critical components of survivorship care."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1b;N0;M0;IA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1b (Tumor >1 cm but ≤2 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1b N0 M0 corresponds to Stage IA2.  Evidence-Based Treatment Plan:

Primary Treatment – Surgery:

Lobectomy is the preferred surgical approach due to its higher curative potential.
Segmentectomy or wedge resection may be considered in:
Patients with small tumors.
Individuals with limited pulmonary reserve or other comorbidities precluding lobectomy.
In all cases, systematic lymph node dissection or sampling should be performed to assess nodal involvement.
Non-Surgical Candidates:

If surgery is contraindicated due to poor cardiopulmonary status or serious comorbid conditions, stereotactic body radiation therapy (SBRT) is the recommended curative alternative.
Other external beam radiation therapies or ablation techniques may be considered when SBRT is not suitable.
Adjuvant Therapy:

Routine adjuvant chemotherapy or immunotherapy is not recommended for patients with completely resected Stage IA NSCLC, as no survival benefit has been consistently demonstrated.
In cases of positive surgical margins, re-resection or adjuvant radiotherapy may be considered.
Participation in clinical trials may be offered to patients at high risk for recurrence.
Follow-up and Surveillance:

Patients should undergo regular follow-up with imaging (e.g., chest CT) and clinical evaluation:
Every 3 months for the first 2 years.
Every 6 months for the next 3 years.
Annually after 5 years.
Smoking cessation should be strongly encouraged, as it improves survival and reduces the risk of recurrence or second primary lung cancers.
Late-onset and long-term side effects of treatment must be monitored.
Summary:
Surgical resection, particularly lobectomy, remains the cornerstone of curative therapy for Stage IA NSCLC. SBRT is an effective non-surgical option for inoperable patients. Routine adjuvant therapy is not recommended unless high-risk features or incomplete resection are present. Close surveillance and smoking cessation are critical components of survivorship care."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1c;N0;M0;IA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1c (Tumor >2 cm but ≤3 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1c N0 M0 corresponds to Stage IA3.  Evidence-Based Treatment Plan:

Primary Treatment – Surgery:

Lobectomy is the preferred surgical approach due to its higher curative potential.
Segmentectomy or wedge resection may be considered in:
Patients with small tumors.
Individuals with limited pulmonary reserve or other comorbidities precluding lobectomy.
In all cases, systematic lymph node dissection or sampling should be performed to assess nodal involvement.
Non-Surgical Candidates:

If surgery is contraindicated due to poor cardiopulmonary status or serious comorbid conditions, stereotactic body radiation therapy (SBRT) is the recommended curative alternative.
Other external beam radiation therapies or ablation techniques may be considered when SBRT is not suitable.
Adjuvant Therapy:

Routine adjuvant chemotherapy or immunotherapy is not recommended for patients with completely resected Stage IA NSCLC, as no survival benefit has been consistently demonstrated.
In cases of positive surgical margins, re-resection or adjuvant radiotherapy may be considered.
Participation in clinical trials may be offered to patients at high risk for recurrence.
Follow-up and Surveillance:

Patients should undergo regular follow-up with imaging (e.g., chest CT) and clinical evaluation:
Every 3 months for the first 2 years.
Every 6 months for the next 3 years.
Annually after 5 years.
Smoking cessation should be strongly encouraged, as it improves survival and reduces the risk of recurrence or second primary lung cancers.
Late-onset and long-term side effects of treatment must be monitored.
Summary:
Surgical resection, particularly lobectomy, remains the cornerstone of curative therapy for Stage IA NSCLC. SBRT is an effective non-surgical option for inoperable patients. Routine adjuvant therapy is not recommended unless high-risk features or incomplete resection are present. Close surveillance and smoking cessation are critical components of survivorship care."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2a;N0;M0;IB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2a (Tumor  ≤4 cm or if the size cannot be
determined. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2a N0 M0 corresponds to Stage IB.  Evidence-Based Treatment Plan:

Primary Treatment – Surgery:

Lobectomy remains the preferred surgical approach due to its curative potential.
Segmentectomy, wedge resection, or sleeve resection may be selected based on tumor characteristics (size/location) and the patient's pulmonary reserve or comorbidities.
All surgical approaches should include systematic lymph node dissection or sampling for accurate staging and detection of occult metastasis.
Adjuvant Therapy Considerations:

Adjuvant chemotherapy may be considered only in select patients with tumors larger than 4 cm or with other high-risk pathological features, but evidence of benefit remains limited outside clinical trials.
Targeted adjuvant therapy is recommended in the following genomic contexts:
EGFR-mutant tumors: Osimertinib.
ALK-rearranged tumors: Alectinib.
Adjuvant immunotherapy (e.g., pembrolizumab) may also be considered for tumors larger than 4 cm.
Routine postoperative radiation therapy (PORT) is not recommended in completely resected Stage IB NSCLC.
Intraoperative brachytherapy during sublobar resections has not shown survival benefit.
Non-Surgical Candidates:

For patients who are medically inoperable, the following curative-intent radiation therapies are recommended:
Stereotactic Body Radiation Therapy (SBRT) is preferred due to:
High local control (90–95%)
Acceptable 2-year overall survival (50–60%)
Low pulmonary toxicity (<10%)
Alternatives include:
External beam radiation therapy (EBRT)
Hypofractionated radiotherapy
Intensity-modulated radiation therapy (IMRT)
Clinical Trials:

Patients at high risk of recurrence or with tumors >4 cm may be eligible for clinical trials evaluating adjuvant chemotherapy or radiotherapy post-surgery.
However, neither modality has shown a consistent survival benefit in completely resected Stage I NSCLC to date.
Follow-Up and Survivorship Care:

Structured surveillance is critical:
CT imaging every 3 months during the first 2 years.
Every 6 months in years 3–5.
Annually after 5 years.
Smoking cessation is essential, even in early-stage disease, to:
Improve long-term survival.
Reduce risk of recurrence and second primary lung cancers.
Long-term monitoring for late toxicities and new symptoms is important, as delayed treatment effects may emerge."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2b;N0;M0;IIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2b (Tumor >4 cm but ≤5 cm in greatest dimension. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2b N0 M0 corresponds to Stage IIA.  Neoadjuvant (Preoperative) Therapy
Neoadjuvant chemotherapy, with or without immunotherapy, is frequently initiated in Stage IIA NSCLC to:

Downstage the tumor and facilitate complete surgical resection.
Eradicate micrometastatic disease.
Potentially improve tolerability compared to postoperative therapy.
Combination of platinum-based chemotherapy and immune checkpoint inhibition may be administered in a perioperative setting.
2. Surgical Management
Surgery is the treatment of choice for resectable Stage IIA NSCLC and may include:

Lobectomy (preferred for curative intent).
Sleeve resection, segmentectomy, or wedge resection when anatomically or functionally indicated.
Pneumonectomy in cases of centrally located tumors requiring broader resection.
A comprehensive mediastinal and hilar lymphadenectomy is performed to assess nodal involvement.

If positive surgical margins are detected, a second surgery may be undertaken to achieve complete resection.
3. Adjuvant (Postoperative) Therapy
Adjuvant cisplatin-based chemotherapy has demonstrated a significant survival advantage for patients with completely resected Stage II NSCLC and is considered standard of care.

Adjuvant targeted therapy:

Osimertinib is recommended for patients with EGFR-mutated tumors, based on improved overall survival (OS) demonstrated in Phase III trials.
Adjuvant immunotherapy options include:

Atezolizumab, pembrolizumab, and durvalumab—especially in patients with tumors >4 cm or expressing PD-L1.
These agents are also components of ongoing perioperative strategies being explored in Phase III studies.
Adjuvant radiation therapy:

Not routinely indicated following complete (R0) surgical resection of Stage II NSCLC.
Its role remains investigational and is not associated with clear survival benefit in this setting.
4. Non-Surgical Management (Medically Inoperable Patients)
For patients with contraindications to surgery, definitive radiation therapy with curative intent is recommended.

Acceptable radiation modalities:

Conventional external beam radiation therapy (EBRT), typically to 60 Gy, delivered with megavoltage equipment.
Hypofractionated radiation therapy.
Stereotactic Body Radiation Therapy (SBRT) when anatomically suitable.
Advanced treatment planning with simulation is essential for accurate tumor targeting and organ sparing.

Among patients with excellent performance status, 3-year overall survival may approach 20% following curative-intent radiation."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1a;N1;M0;IIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1a (Tumor ≤1 cm in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. Tumor Surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1a N1 M0 corresponds to Stage IIB.  Surgical Management (Resectable Disease)
Surgery remains the treatment of choice for operable Stage IIB NSCLC and may involve:

Lobectomy (standard of care).
Pneumonectomy, sleeve resection, segmentectomy, or wedge resection based on tumor location and patient operability.
A systematic lymph node dissection is routinely performed for accurate staging and prognostication.
Preoperative assessment is essential to evaluate cardiopulmonary function and determine surgical fitness. Operative risks include:

3–5% mortality with lobectomy.
5–8% mortality with pneumonectomy.
2. Neoadjuvant (Preoperative) Therapy
Neoadjuvant platinum-based chemotherapy may be administered before surgery to:

Reduce tumor burden.
Target micrometastatic disease.
Improve surgical outcomes.
Neoadjuvant chemo-immunotherapy has demonstrated benefit. Agents include:

Nivolumab + platinum-doublet chemotherapy.
Pembrolizumab, durvalumab, or toripalimab in combination with chemotherapy, as part of perioperative strategies.
3. Adjuvant (Postoperative) Therapy
Post-surgical therapy is guided by pathological findings, molecular profile, and PD-L1 status:

Adjuvant chemotherapy (cisplatin-based) is strongly recommended for resected Stage IIB disease and improves survival outcomes.

Adjuvant targeted therapy:

Osimertinib is indicated for patients with EGFR mutations, based on phase III trial data showing improved overall survival.
Adjuvant immunotherapy:

Atezolizumab, pembrolizumab, or durvalumab may be considered for PD-L1–expressing tumors.
These agents have been incorporated into perioperative treatment paradigms as well.
Adjuvant radiation therapy:

May be considered in select high-risk cases, but has not demonstrated a survival benefit in completely resected Stage II NSCLC.
4. Perioperative Immunotherapy Strategies
Emerging perioperative regimens (both neoadjuvant and adjuvant) include:

Nivolumab, pembrolizumab, durvalumab, or toripalimab in combination with platinum-based chemotherapy.
These combinations are supported by ongoing clinical trials and have shown improved outcomes in:
Event-Free Survival (EFS).
Pathological Complete Response (pCR).
Overall Survival (OS).
5. Definitive Non-Surgical Management
For patients who are medically inoperable, definitive radiation therapy is the mainstay of curative-intent treatment:

Standard EBRT: 60 Gy delivered using megavoltage equipment with conventional fractionation.

SBRT (Stereotactic Body Radiation Therapy): May be used when technically feasible.

Hypofractionated regimens may also be considered.

Careful radiotherapy planning is crucial:

Includes simulation, accurate tumor volume delineation, and normal tissue sparing.
For medically inoperable patients with excellent performance status, 3-year overall survival may reach 20% with curative radiation.

Summary
Management of Stage IIB NSCLC involves a multimodal strategy tailored to resectability, biomarker status, and performance status. Surgical resection (lobectomy preferred) is central for operable disease, often preceded by neoadjuvant chemotherapy ± immunotherapy. Adjuvant cisplatin-based chemotherapy is standard; targeted agents like osimertinib (EGFR-mutant) and immune checkpoint inhibitors (PD-L1+) may be incorporated. Radiotherapy with curative intent remains a definitive option for non-surgical candidates. Perioperative immuno-chemotherapy combinations are emerging as key components of modern management.  Regular follow-up with CT scans and clinical assessment to monitor for recurrence or treatment-related complications."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1b;N1;M0;IIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1b (Tumor >1 cm but ≤2 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1b N1 M0 corresponds to Stage IIB.  Surgical Management (Resectable Disease)
Surgery remains the treatment of choice for operable Stage IIB NSCLC and may involve:

Lobectomy (standard of care).
Pneumonectomy, sleeve resection, segmentectomy, or wedge resection based on tumor location and patient operability.
A systematic lymph node dissection is routinely performed for accurate staging and prognostication.
Preoperative assessment is essential to evaluate cardiopulmonary function and determine surgical fitness. Operative risks include:

3–5% mortality with lobectomy.
5–8% mortality with pneumonectomy.
2. Neoadjuvant (Preoperative) Therapy
Neoadjuvant platinum-based chemotherapy may be administered before surgery to:

Reduce tumor burden.
Target micrometastatic disease.
Improve surgical outcomes.
Neoadjuvant chemo-immunotherapy has demonstrated benefit. Agents include:

Nivolumab + platinum-doublet chemotherapy.
Pembrolizumab, durvalumab, or toripalimab in combination with chemotherapy, as part of perioperative strategies.
3. Adjuvant (Postoperative) Therapy
Post-surgical therapy is guided by pathological findings, molecular profile, and PD-L1 status:

Adjuvant chemotherapy (cisplatin-based) is strongly recommended for resected Stage IIB disease and improves survival outcomes.

Adjuvant targeted therapy:

Osimertinib is indicated for patients with EGFR mutations, based on phase III trial data showing improved overall survival.
Adjuvant immunotherapy:

Atezolizumab, pembrolizumab, or durvalumab may be considered for PD-L1–expressing tumors.
These agents have been incorporated into perioperative treatment paradigms as well.
Adjuvant radiation therapy:

May be considered in select high-risk cases, but has not demonstrated a survival benefit in completely resected Stage II NSCLC.
4. Perioperative Immunotherapy Strategies
Emerging perioperative regimens (both neoadjuvant and adjuvant) include:

Nivolumab, pembrolizumab, durvalumab, or toripalimab in combination with platinum-based chemotherapy.
These combinations are supported by ongoing clinical trials and have shown improved outcomes in:
Event-Free Survival (EFS).
Pathological Complete Response (pCR).
Overall Survival (OS).
5. Definitive Non-Surgical Management
For patients who are medically inoperable, definitive radiation therapy is the mainstay of curative-intent treatment:

Standard EBRT: 60 Gy delivered using megavoltage equipment with conventional fractionation.

SBRT (Stereotactic Body Radiation Therapy): May be used when technically feasible.

Hypofractionated regimens may also be considered.

Careful radiotherapy planning is crucial:

Includes simulation, accurate tumor volume delineation, and normal tissue sparing.
For medically inoperable patients with excellent performance status, 3-year overall survival may reach 20% with curative radiation.

Summary
Management of Stage IIB NSCLC involves a multimodal strategy tailored to resectability, biomarker status, and performance status. Surgical resection (lobectomy preferred) is central for operable disease, often preceded by neoadjuvant chemotherapy ± immunotherapy. Adjuvant cisplatin-based chemotherapy is standard; targeted agents like osimertinib (EGFR-mutant) and immune checkpoint inhibitors (PD-L1+) may be incorporated. Radiotherapy with curative intent remains a definitive option for non-surgical candidates. Perioperative immuno-chemotherapy combinations are emerging as key components of modern management.  Regular follow-up with CT scans and clinical assessment to monitor for recurrence or treatment-related complications."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1c;N1;M0;IIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1c (Tumor >2 cm but ≤3 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1c N1 M0 corresponds to Stage IIB.  Surgical Management (Resectable Disease)
Surgery remains the treatment of choice for operable Stage IIB NSCLC and may involve:

Lobectomy (standard of care).
Pneumonectomy, sleeve resection, segmentectomy, or wedge resection based on tumor location and patient operability.
A systematic lymph node dissection is routinely performed for accurate staging and prognostication.
Preoperative assessment is essential to evaluate cardiopulmonary function and determine surgical fitness. Operative risks include:

3–5% mortality with lobectomy.
5–8% mortality with pneumonectomy.
2. Neoadjuvant (Preoperative) Therapy
Neoadjuvant platinum-based chemotherapy may be administered before surgery to:

Reduce tumor burden.
Target micrometastatic disease.
Improve surgical outcomes.
Neoadjuvant chemo-immunotherapy has demonstrated benefit. Agents include:

Nivolumab + platinum-doublet chemotherapy.
Pembrolizumab, durvalumab, or toripalimab in combination with chemotherapy, as part of perioperative strategies.
3. Adjuvant (Postoperative) Therapy
Post-surgical therapy is guided by pathological findings, molecular profile, and PD-L1 status:

Adjuvant chemotherapy (cisplatin-based) is strongly recommended for resected Stage IIB disease and improves survival outcomes.

Adjuvant targeted therapy:

Osimertinib is indicated for patients with EGFR mutations, based on phase III trial data showing improved overall survival.
Adjuvant immunotherapy:

Atezolizumab, pembrolizumab, or durvalumab may be considered for PD-L1–expressing tumors.
These agents have been incorporated into perioperative treatment paradigms as well.
Adjuvant radiation therapy:

May be considered in select high-risk cases, but has not demonstrated a survival benefit in completely resected Stage II NSCLC.
4. Perioperative Immunotherapy Strategies
Emerging perioperative regimens (both neoadjuvant and adjuvant) include:

Nivolumab, pembrolizumab, durvalumab, or toripalimab in combination with platinum-based chemotherapy.
These combinations are supported by ongoing clinical trials and have shown improved outcomes in:
Event-Free Survival (EFS).
Pathological Complete Response (pCR).
Overall Survival (OS).
5. Definitive Non-Surgical Management
For patients who are medically inoperable, definitive radiation therapy is the mainstay of curative-intent treatment:

Standard EBRT: 60 Gy delivered using megavoltage equipment with conventional fractionation.

SBRT (Stereotactic Body Radiation Therapy): May be used when technically feasible.

Hypofractionated regimens may also be considered.

Careful radiotherapy planning is crucial:

Includes simulation, accurate tumor volume delineation, and normal tissue sparing.
For medically inoperable patients with excellent performance status, 3-year overall survival may reach 20% with curative radiation.

Summary
Management of Stage IIB NSCLC involves a multimodal strategy tailored to resectability, biomarker status, and performance status. Surgical resection (lobectomy preferred) is central for operable disease, often preceded by neoadjuvant chemotherapy ± immunotherapy. Adjuvant cisplatin-based chemotherapy is standard; targeted agents like osimertinib (EGFR-mutant) and immune checkpoint inhibitors (PD-L1+) may be incorporated. Radiotherapy with curative intent remains a definitive option for non-surgical candidates. Perioperative immuno-chemotherapy combinations are emerging as key components of modern management.  Regular follow-up with CT scans and clinical assessment to monitor for recurrence or treatment-related complications."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2a;N1;M0;IIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2a (Tumor  ≤4 cm or if the size cannot be
determined. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2a N1 M0 corresponds to Stage IIB.  Surgical Management (Resectable Disease)
Surgery remains the treatment of choice for operable Stage IIB NSCLC and may involve:

Lobectomy (standard of care).
Pneumonectomy, sleeve resection, segmentectomy, or wedge resection based on tumor location and patient operability.
A systematic lymph node dissection is routinely performed for accurate staging and prognostication.
Preoperative assessment is essential to evaluate cardiopulmonary function and determine surgical fitness. Operative risks include:

3–5% mortality with lobectomy.
5–8% mortality with pneumonectomy.
2. Neoadjuvant (Preoperative) Therapy
Neoadjuvant platinum-based chemotherapy may be administered before surgery to:

Reduce tumor burden.
Target micrometastatic disease.
Improve surgical outcomes.
Neoadjuvant chemo-immunotherapy has demonstrated benefit. Agents include:

Nivolumab + platinum-doublet chemotherapy.
Pembrolizumab, durvalumab, or toripalimab in combination with chemotherapy, as part of perioperative strategies.
3. Adjuvant (Postoperative) Therapy
Post-surgical therapy is guided by pathological findings, molecular profile, and PD-L1 status:

Adjuvant chemotherapy (cisplatin-based) is strongly recommended for resected Stage IIB disease and improves survival outcomes.

Adjuvant targeted therapy:

Osimertinib is indicated for patients with EGFR mutations, based on phase III trial data showing improved overall survival.
Adjuvant immunotherapy:

Atezolizumab, pembrolizumab, or durvalumab may be considered for PD-L1–expressing tumors.
These agents have been incorporated into perioperative treatment paradigms as well.
Adjuvant radiation therapy:

May be considered in select high-risk cases, but has not demonstrated a survival benefit in completely resected Stage II NSCLC.
4. Perioperative Immunotherapy Strategies
Emerging perioperative regimens (both neoadjuvant and adjuvant) include:

Nivolumab, pembrolizumab, durvalumab, or toripalimab in combination with platinum-based chemotherapy.
These combinations are supported by ongoing clinical trials and have shown improved outcomes in:
Event-Free Survival (EFS).
Pathological Complete Response (pCR).
Overall Survival (OS).
5. Definitive Non-Surgical Management
For patients who are medically inoperable, definitive radiation therapy is the mainstay of curative-intent treatment:

Standard EBRT: 60 Gy delivered using megavoltage equipment with conventional fractionation.

SBRT (Stereotactic Body Radiation Therapy): May be used when technically feasible.

Hypofractionated regimens may also be considered.

Careful radiotherapy planning is crucial:

Includes simulation, accurate tumor volume delineation, and normal tissue sparing.
For medically inoperable patients with excellent performance status, 3-year overall survival may reach 20% with curative radiation.

Summary
Management of Stage IIB NSCLC involves a multimodal strategy tailored to resectability, biomarker status, and performance status. Surgical resection (lobectomy preferred) is central for operable disease, often preceded by neoadjuvant chemotherapy ± immunotherapy. Adjuvant cisplatin-based chemotherapy is standard; targeted agents like osimertinib (EGFR-mutant) and immune checkpoint inhibitors (PD-L1+) may be incorporated. Radiotherapy with curative intent remains a definitive option for non-surgical candidates. Perioperative immuno-chemotherapy combinations are emerging as key components of modern management.  Regular follow-up with CT scans and clinical assessment to monitor for recurrence or treatment-related complications."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2b;N1;M0;IIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2b (Tumor >4 cm but ≤5 cm in greatest dimension. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2b N1 M0 corresponds to Stage IIB.  Surgical Management (Resectable Disease)
Surgery remains the treatment of choice for operable Stage IIB NSCLC and may involve:

Lobectomy (standard of care).
Pneumonectomy, sleeve resection, segmentectomy, or wedge resection based on tumor location and patient operability.
A systematic lymph node dissection is routinely performed for accurate staging and prognostication.
Preoperative assessment is essential to evaluate cardiopulmonary function and determine surgical fitness. Operative risks include:

3–5% mortality with lobectomy.
5–8% mortality with pneumonectomy.
2. Neoadjuvant (Preoperative) Therapy
Neoadjuvant platinum-based chemotherapy may be administered before surgery to:

Reduce tumor burden.
Target micrometastatic disease.
Improve surgical outcomes.
Neoadjuvant chemo-immunotherapy has demonstrated benefit. Agents include:

Nivolumab + platinum-doublet chemotherapy.
Pembrolizumab, durvalumab, or toripalimab in combination with chemotherapy, as part of perioperative strategies.
3. Adjuvant (Postoperative) Therapy
Post-surgical therapy is guided by pathological findings, molecular profile, and PD-L1 status:

Adjuvant chemotherapy (cisplatin-based) is strongly recommended for resected Stage IIB disease and improves survival outcomes.

Adjuvant targeted therapy:

Osimertinib is indicated for patients with EGFR mutations, based on phase III trial data showing improved overall survival.
Adjuvant immunotherapy:

Atezolizumab, pembrolizumab, or durvalumab may be considered for PD-L1–expressing tumors.
These agents have been incorporated into perioperative treatment paradigms as well.
Adjuvant radiation therapy:

May be considered in select high-risk cases, but has not demonstrated a survival benefit in completely resected Stage II NSCLC.
4. Perioperative Immunotherapy Strategies
Emerging perioperative regimens (both neoadjuvant and adjuvant) include:

Nivolumab, pembrolizumab, durvalumab, or toripalimab in combination with platinum-based chemotherapy.
These combinations are supported by ongoing clinical trials and have shown improved outcomes in:
Event-Free Survival (EFS).
Pathological Complete Response (pCR).
Overall Survival (OS).
5. Definitive Non-Surgical Management
For patients who are medically inoperable, definitive radiation therapy is the mainstay of curative-intent treatment:

Standard EBRT: 60 Gy delivered using megavoltage equipment with conventional fractionation.

SBRT (Stereotactic Body Radiation Therapy): May be used when technically feasible.

Hypofractionated regimens may also be considered.

Careful radiotherapy planning is crucial:

Includes simulation, accurate tumor volume delineation, and normal tissue sparing.
For medically inoperable patients with excellent performance status, 3-year overall survival may reach 20% with curative radiation.

Summary
Management of Stage IIB NSCLC involves a multimodal strategy tailored to resectability, biomarker status, and performance status. Surgical resection (lobectomy preferred) is central for operable disease, often preceded by neoadjuvant chemotherapy ± immunotherapy. Adjuvant cisplatin-based chemotherapy is standard; targeted agents like osimertinib (EGFR-mutant) and immune checkpoint inhibitors (PD-L1+) may be incorporated. Radiotherapy with curative intent remains a definitive option for non-surgical candidates. Perioperative immuno-chemotherapy combinations are emerging as key components of modern management.  Regular follow-up with CT scans and clinical assessment to monitor for recurrence or treatment-related complications."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T3;N0;M0;IIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T3 (Tumor >5 cm but ≤7 cm in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary.)
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T3 N0 M0 corresponds to Stage IIB.  Surgical Management (Resectable Disease)
Surgery remains the treatment of choice for operable Stage IIB NSCLC and may involve:

Lobectomy (standard of care).
Pneumonectomy, sleeve resection, segmentectomy, or wedge resection based on tumor location and patient operability.
A systematic lymph node dissection is routinely performed for accurate staging and prognostication.
Preoperative assessment is essential to evaluate cardiopulmonary function and determine surgical fitness. Operative risks include:

3–5% mortality with lobectomy.
5–8% mortality with pneumonectomy.
2. Neoadjuvant (Preoperative) Therapy
Neoadjuvant platinum-based chemotherapy may be administered before surgery to:

Reduce tumor burden.
Target micrometastatic disease.
Improve surgical outcomes.
Neoadjuvant chemo-immunotherapy has demonstrated benefit. Agents include:

Nivolumab + platinum-doublet chemotherapy.
Pembrolizumab, durvalumab, or toripalimab in combination with chemotherapy, as part of perioperative strategies.
3. Adjuvant (Postoperative) Therapy
Post-surgical therapy is guided by pathological findings, molecular profile, and PD-L1 status:

Adjuvant chemotherapy (cisplatin-based) is strongly recommended for resected Stage IIB disease and improves survival outcomes.

Adjuvant targeted therapy:

Osimertinib is indicated for patients with EGFR mutations, based on phase III trial data showing improved overall survival.
Adjuvant immunotherapy:

Atezolizumab, pembrolizumab, or durvalumab may be considered for PD-L1–expressing tumors.
These agents have been incorporated into perioperative treatment paradigms as well.
Adjuvant radiation therapy:

May be considered in select high-risk cases, but has not demonstrated a survival benefit in completely resected Stage II NSCLC.
4. Perioperative Immunotherapy Strategies
Emerging perioperative regimens (both neoadjuvant and adjuvant) include:

Nivolumab, pembrolizumab, durvalumab, or toripalimab in combination with platinum-based chemotherapy.
These combinations are supported by ongoing clinical trials and have shown improved outcomes in:
Event-Free Survival (EFS).
Pathological Complete Response (pCR).
Overall Survival (OS).
5. Definitive Non-Surgical Management
For patients who are medically inoperable, definitive radiation therapy is the mainstay of curative-intent treatment:

Standard EBRT: 60 Gy delivered using megavoltage equipment with conventional fractionation.

SBRT (Stereotactic Body Radiation Therapy): May be used when technically feasible.

Hypofractionated regimens may also be considered.

Careful radiotherapy planning is crucial:

Includes simulation, accurate tumor volume delineation, and normal tissue sparing.
For medically inoperable patients with excellent performance status, 3-year overall survival may reach 20% with curative radiation.

Summary
Management of Stage IIB NSCLC involves a multimodal strategy tailored to resectability, biomarker status, and performance status. Surgical resection (lobectomy preferred) is central for operable disease, often preceded by neoadjuvant chemotherapy ± immunotherapy. Adjuvant cisplatin-based chemotherapy is standard; targeted agents like osimertinib (EGFR-mutant) and immune checkpoint inhibitors (PD-L1+) may be incorporated. Radiotherapy with curative intent remains a definitive option for non-surgical candidates. Perioperative immuno-chemotherapy combinations are emerging as key components of modern management.  Regular follow-up with CT scans and clinical assessment to monitor for recurrence or treatment-related complications."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1a;N2;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1a (Tumor ≤1 cm in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. Tumor Surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1a  N2 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1b;N2;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1b (Tumor >1 cm but ≤2 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1b N2 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1c;N2;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1c (Tumor >2 cm but ≤3 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1c N2 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2a;N2;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2a (Tumor  ≤4 cm or if the size cannot be
determined. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2a N2 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2b;N2;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2b (Tumor >4 cm but ≤5 cm in greatest dimension. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2b N2 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T3;N1;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T3 (Tumor >5 cm but ≤7 cm in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary.)
- Lymph Node (N) Stage: N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph
nodes and intrapulmonary nodes, including involvement by direct
extension.)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T3 N1 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T4;N0;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T4 (Tumor >7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary)
- Lymph Node (N) Stage: N0 (No regional lymph node metastasis)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T4 N0 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T4;N1;M0;IIIA;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T4 (Tumor >7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary)
- Lymph Node (N) Stage:  N1 (Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension)
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T4 N1 M0 corresponds to Stage IIIA.  Resectable Stage IIIA NSCLC
1. Neoadjuvant Therapy (Preferred Initial Strategy):

Platinum-based neoadjuvant chemotherapy (e.g., cisplatin + docetaxel or vinorelbine).
Neoadjuvant chemoradiation (in select cases to improve mediastinal control).
Neoadjuvant immunotherapy + chemotherapy:
Nivolumab + platinum-based chemotherapy, as validated by the CheckMate 816 trial.
Perioperative chemo-immunotherapy combinations:
Pembrolizumab, nivolumab, durvalumab, or toripalimab + platinum-based chemotherapy.
2. Surgical Resection (Post-Neoadjuvant Therapy):

Anatomic resection: Lobectomy (preferred), pneumonectomy, sleeve resection, or segmentectomy (if functionally required).
Mandatory complete ipsilateral mediastinal lymph node dissection (CMLND) to ensure accurate staging and reduce recurrence risk.
3. Adjuvant Therapy (Based on Resected Pathology and Molecular Markers):

Adjuvant chemotherapy: Cisplatin-based combinations for improved overall survival (especially in patients with N2 disease).
Adjuvant targeted therapy:
Osimertinib (for EGFR mutations).
Alectinib (for ALK rearrangements).
Adjuvant immunotherapy:
Pembrolizumab, atezolizumab, or durvalumab, particularly in PD-L1–positive tumors.
Adjuvant chemoradiation: Considered in cases with high-risk features such as positive margins or extracapsular extension.
Adjuvant radiation therapy: Used selectively for patients with unclear surgical margins or nodal residual disease.
Special Considerations:

Chest wall invasion: May require surgery + adjuvant radiotherapy or multimodal therapy (chemoradiation + surgery).
Superior sulcus (Pancoast) tumors: Treat with induction chemoradiation, followed by surgical resection when feasible.
 Unresectable Stage IIIA NSCLC
1. Concurrent Chemoradiation Therapy (Standard of Care):

Combination of platinum-based chemotherapy + EBRT (External Beam Radiation Therapy).
Typical radiation dose: ~60 Gy in conventional fractions.
2. Consolidation Immunotherapy (Post-Chemoradiation):

Durvalumab for up to 12 months (based on PACIFIC trial) in patients with no progression after chemoradiation.
3. Non-Surgical/Alternative Options (For Poor Performance Status):

Monotherapy with immunotherapy: Pembrolizumab or cemiplimab (in PD-L1–positive patients).
Palliative interventions:
Internal radiation (brachytherapy) or endobronchial laser surgery for airway obstruction or hemoptysis.
Radiation therapy for relief of superior vena cava syndrome, vocal cord paralysis, or compressive symptoms.
Biomarker-Guided Therapies
EGFR-mutant NSCLC: Adjuvant osimertinib following surgery.
ALK-positive disease: Adjuvant alectinib may be considered.
PD-L1 positive tumors: Eligible for durvalumab, pembrolizumab, or atezolizumab based on expression levels and treatment sequence.
Clinical Trials
Recommend enrollment in ongoing phase III studies investigating perioperative checkpoint inhibitors, novel immunotherapies, or personalized adjuvant strategies.
Non-Surgical Management Summary
For patients who are medically inoperable or have unresectable tumors:
Concurrent chemoradiation + consolidation durvalumab (if fit).
SBRT or hypofractionated EBRT if radiation is the only feasible option.
Immune checkpoint inhibitor monotherapy for patients with high PD-L1 expression who cannot tolerate radiation/chemo.
Precise radiotherapy planning using simulation and megavoltage equipment to optimize local control and preserve organ function."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1a;N3;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1a (Tumor ≤1 cm in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. Tumor Surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, Tia N3 M0 corresponds to Stage IIIB.  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1b;N3;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1b (Tumor >1 cm but ≤2 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1b N3 M0 corresponds to Stage IIIB.  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T1c;N3;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T1c (Tumor >2 cm but ≤3 cm in greatest dimension. Tumor Surrounded by lung or visceral
pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus))
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T1c N3 M0 corresponds to Stage IIIB.  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2a;N3;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2a (Tumor  ≤4 cm or if the size cannot be
determined. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2a N3 M0 corresponds to Stage IIIB .  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T2b;N3;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T2b (Tumor >4 cm but ≤5 cm in greatest dimension. Involves the main bronchus regardless of distance to the carina, but without involvement of the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung)
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T2b N3 M0 corresponds to Stage IIIB.  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T3;N2;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T3 (Tumor >5 cm but ≤7 cm in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary.)
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T3 N2 M0 corresponds to Stage IIIB.  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T4;N2;M0;IIIB;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T4 (Tumor >7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary)
- Lymph Node (N) Stage: N2 (Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T4 N2 M0 corresponds to Stage IIIB.  Stage IIIB  is considered unresectable due to the extent of nodal or local thoracic involvement. Therefore, surgical intervention is not standard of care, and treatment is directed toward multimodal non-surgical management, tailored to patient performance status and molecular profile.

Evidence-Based Treatment Plan
Primary Treatment Modality: Concurrent or Sequential Chemoradiotherapy
Concurrent chemoradiation is the preferred treatment for patients with good performance status (ECOG 0–1) and adequate pulmonary reserve:

Platinum-based chemotherapy (e.g., cisplatin + etoposide or carboplatin + paclitaxel) administered concurrently with external beam radiation therapy (EBRT).
Radiation dose: 60–70 Gy in 1.8–2.0 Gy fractions over 6–7 weeks.
Sequential chemoradiation (induction chemotherapy followed by EBRT) is an alternative for patients who cannot tolerate concurrent treatment.

Radiation dose escalation, radiosensitizers, and adaptive radiation guided by PET-CT are being explored in clinical trials.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1) for up to 12 months is the standard consolidation immunotherapy for patients who do not show disease progression after definitive chemoradiation. This improves progression-free and overall survival.

In patients with EGFR mutations, osimertinib may be considered as consolidation therapy, although optimal sequencing with immunotherapy is under investigation.

Alternative Approaches (For Non-Candidates for Chemoradiation)
Radiation therapy alone is appropriate for:

Patients with locally advanced, unresectable NSCLC and poor performance status (ECOG ≥2).
Delivered using standard fractionation (e.g., 60 Gy in 30–33 fractions).
Systemic chemotherapy alone may be considered if radiation is contraindicated.

Systemic immunotherapy alone:

Pembrolizumab or cemiplimab can be administered in patients with PD-L1–positive tumors who cannot tolerate chemoradiation or other local therapies.
Targeted Therapy and Molecular Considerations
EGFR-mutated tumors: Consider osimertinib before or after chemoradiation, as part of a personalized approach.
ALK-rearranged tumors: Though data is limited, integration of ALK inhibitors in multimodal settings may be explored through clinical trials.
Palliative Strategies (For Symptom Management or Advanced Disease)
Patients with bulky mediastinal involvement or poor performance status may require:

Endobronchial brachytherapy, laser therapy, or external palliative radiation for:
Tracheal or esophageal obstruction
Hemoptysis
Pain due to chest wall involvement
Vocal cord paralysis
Superior vena cava (SVC) syndrome
Clinical Trials and Investigational Approaches
Patients with Stage IIIB NSCLC should be referred to clinical trials"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T3;N3;M0;IIIC;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T3 (Tumor >5 cm but ≤7 cm in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary.)
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T3 N3 M0 corresponds to Stage IIIC.  Surgical resection offers no proven survival benefit and is not routinely indicated. Treatment is centered on aggressive multimodal non-surgical therapy.

Evidence-Based Treatment Plan
First-Line Treatment for Patients with Good Performance Status (ECOG 0–1)
Concurrent chemoradiation therapy (cCRT) is the standard of care and provides the best chance for durable local control and improved overall survival:

Platinum-doublet chemotherapy (e.g., cisplatin + etoposide, carboplatin + paclitaxel),
Concurrent external beam radiation therapy (60–70 Gy, 1.8–2.0 Gy per fraction over 6–7 weeks).
Sequential chemoradiation (chemotherapy followed by radiation) is an option for patients unable to tolerate concurrent regimens.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1 monoclonal antibody) is recommended as consolidation immunotherapy for up to 12 months in patients without disease progression after chemoradiation.

In patients with EGFR mutations, osimertinib may be considered in the consolidation setting. Integration into combined-modality therapy is under evaluation in clinical trials.

Alternative Options for Non-Candidates for Chemoradiation
For patients with poor functional status, comorbidities, or intolerance to systemic therapy:

Radiation therapy alone using conventional dosing (e.g., 60–70 Gy) may offer symptomatic relief and local control in selected cases.

Systemic therapy alone:

Immunotherapy (e.g., pembrolizumab, cemiplimab) may be used in tumors with high PD-L1 expression when radiation and chemotherapy are contraindicated.
Targeted therapies (e.g., osimertinib for EGFR+, alectinib for ALK+) may be considered in molecularly driven tumors.
Palliative Interventions for Advanced Symptom Management
Patients with advanced symptomatic disease may benefit from:

Palliative radiation therapy for:
Tracheal, esophageal, or bronchial compression,
Superior vena cava (SVC) syndrome,
Hemoptysis, chest pain, or vocal cord paralysis.
Endobronchial therapies such as brachytherapy or laser debulking may be applied to obstructing central tumors.
Clinical Trials and Investigational Therapies
Given the poor long-term prognosis of Stage IIIC NSCLC, enrollment in clinical trials is strongly encouraged"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";T4;N3;M0;IIIC;Not specified;"Based on the provided TNM classification:

- Tumor (T) Stage: T4 (Tumor >7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary)
- Lymph Node (N) Stage: N3 (Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s))
- Metastasis (M) Stage: M0 (No distant metastasis)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, T4 N3 M0 corresponds to Stage IIIC.  Surgical resection offers no proven survival benefit and is not routinely indicated. Treatment is centered on aggressive multimodal non-surgical therapy.

Evidence-Based Treatment Plan
First-Line Treatment for Patients with Good Performance Status (ECOG 0–1)
Concurrent chemoradiation therapy (cCRT) is the standard of care and provides the best chance for durable local control and improved overall survival:

Platinum-doublet chemotherapy (e.g., cisplatin + etoposide, carboplatin + paclitaxel),
Concurrent external beam radiation therapy (60–70 Gy, 1.8–2.0 Gy per fraction over 6–7 weeks).
Sequential chemoradiation (chemotherapy followed by radiation) is an option for patients unable to tolerate concurrent regimens.

Post-Chemoradiation Consolidation Therapy
Durvalumab (anti–PD-L1 monoclonal antibody) is recommended as consolidation immunotherapy for up to 12 months in patients without disease progression after chemoradiation.

In patients with EGFR mutations, osimertinib may be considered in the consolidation setting. Integration into combined-modality therapy is under evaluation in clinical trials.

Alternative Options for Non-Candidates for Chemoradiation
For patients with poor functional status, comorbidities, or intolerance to systemic therapy:

Radiation therapy alone using conventional dosing (e.g., 60–70 Gy) may offer symptomatic relief and local control in selected cases.

Systemic therapy alone:

Immunotherapy (e.g., pembrolizumab, cemiplimab) may be used in tumors with high PD-L1 expression when radiation and chemotherapy are contraindicated.
Targeted therapies (e.g., osimertinib for EGFR+, alectinib for ALK+) may be considered in molecularly driven tumors.
Palliative Interventions for Advanced Symptom Management
Patients with advanced symptomatic disease may benefit from:

Palliative radiation therapy for:
Tracheal, esophageal, or bronchial compression,
Superior vena cava (SVC) syndrome,
Hemoptysis, chest pain, or vocal cord paralysis.
Endobronchial therapies such as brachytherapy or laser debulking may be applied to obstructing central tumors.
Clinical Trials and Investigational Therapies
Given the poor long-term prognosis of Stage IIIC NSCLC, enrollment in clinical trials is strongly encouraged"
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";Any T;Any N;M1a;IVA;Not specified;"Based on the provided TNM classification:

- Metastasis (M) Stage: M1a (Distant metastasis. Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, M1a  corresponds to Stage IVA.  Newly Diagnosed Stage IVA NSCLC
For oligometastatic patients (e.g., single brain/liver/adrenal lesion):

Local ablative treatment (LAT) to metastatic site:
Stereotactic radiosurgery (SRS) or surgical resection for solitary brain/liver/adrenal metastasis.
Surgical resection or SBRT for solitary lung primary.
Followed by systemic therapy tailored to tumor molecular profile and PD-L1 status.
Systemic Therapy Options:

Targeted therapy first-line if oncogenic driver mutation detected:

EGFR mutations: Osimertinib.
ALK rearrangements: Alectinib, Lorlatinib.
ROS1, RET, MET, NTRK, BRAF, KRAS G12C: Matched targeted agents.
Immune checkpoint inhibitors:

PD-L1 ≥50%: Pembrolizumab monotherapy.
PD-L1 <50% or negative: Pembrolizumab + chemotherapy, or other combinations like atezolizumab + bevacizumab + chemo.
Platinum-based chemotherapy (e.g., carboplatin + pemetrexed for nonsquamous NSCLC) for patients without driver mutations.

Palliative procedures (e.g., pleurodesis, indwelling pleural catheter) are recommended for patients with malignant pleural effusion.

Progressive or Recurrent Stage IVA NSCLC
Treatment depends on prior exposure and molecular status:

Immunotherapy after chemotherapy: Nivolumab, pembrolizumab, or atezolizumab if not previously given.

Chemotherapy after IO failure: Docetaxel ± ramucirumab, pemetrexed.

Targeted therapy for acquired mutations:

EGFR T790M: Osimertinib.
ALK progression: Next-generation TKIs (e.g., lorlatinib).
KRAS G12C: Sotorasib or adagrasib.
Consider clinical trials for novel agents (e.g., mTOR inhibitors, HER2-targeted agents)."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";Any T;Any N;M1b;IVA;Not specified;"Based on the provided TNM classification:

- Metastasis (M) Stage: M1b (Distant metastasis. Single extrathoracic metastases in a single organ (including
involvement of a single nonregional node))

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer, M1b corresponds to Stage IVA.  Newly Diagnosed Stage IVA NSCLC
For oligometastatic patients (e.g., single brain/liver/adrenal lesion):

Local ablative treatment (LAT) to metastatic site:
Stereotactic radiosurgery (SRS) or surgical resection for solitary brain/liver/adrenal metastasis.
Surgical resection or SBRT for solitary lung primary.
Followed by systemic therapy tailored to tumor molecular profile and PD-L1 status.
Systemic Therapy Options:

Targeted therapy first-line if oncogenic driver mutation detected:

EGFR mutations: Osimertinib.
ALK rearrangements: Alectinib, Lorlatinib.
ROS1, RET, MET, NTRK, BRAF, KRAS G12C: Matched targeted agents.
Immune checkpoint inhibitors:

PD-L1 ≥50%: Pembrolizumab monotherapy.
PD-L1 <50% or negative: Pembrolizumab + chemotherapy, or other combinations like atezolizumab + bevacizumab + chemo.
Platinum-based chemotherapy (e.g., carboplatin + pemetrexed for nonsquamous NSCLC) for patients without driver mutations.

Palliative procedures (e.g., pleurodesis, indwelling pleural catheter) are recommended for patients with malignant pleural effusion.

Progressive or Recurrent Stage IVA NSCLC
Treatment depends on prior exposure and molecular status:

Immunotherapy after chemotherapy: Nivolumab, pembrolizumab, or atezolizumab if not previously given.

Chemotherapy after IO failure: Docetaxel ± ramucirumab, pemetrexed.

Targeted therapy for acquired mutations:

EGFR T790M: Osimertinib.
ALK progression: Next-generation TKIs (e.g., lorlatinib).
KRAS G12C: Sotorasib or adagrasib.
Consider clinical trials for novel agents (e.g., mTOR inhibitors, HER2-targeted agents)."
"NSCLC - Adenocarcinoma; Large Cell Carcinoma; Squamous Cell Carcinoma ";Any T;Any N;M1c;IVB;Not specified;"Based on the provided TNM classification:

- Metastasis (M) Stage: M1c (Distant metastasis. Multiple extrathoracic metastases in a single organ or in multiple
organs)

According to TNM staging, using the AJCC 8th Edition lung cancer staging system for non-small cell lung cancer,  M1c corresponds to Stage IVB.  Stage IVB NSCLC represents widespread metastatic disease involving multiple extrathoracic organs or sites (M1c). It is considered non-curable, and treatment is primarily palliative with survival and quality-of-life goals.

Evidence-Based Treatment Plan
Newly Diagnosed Stage IVB NSCLC
Comprehensive Molecular Testing is critical:

Test for EGFR, ALK, ROS1, BRAF, NTRK, RET, MET exon 14, KRAS G12C.
Assess PD-L1 expression to guide immunotherapy decisions.
Targeted Therapy Options:

EGFR+: Osimertinib.
ALK+: Alectinib, Lorlatinib.
ROS1+: Entrectinib.
BRAF+: Dabrafenib + Trametinib.
KRAS G12C+: Sotorasib, Adagrasib.
MET exon 14+: Tepotinib, Capmatinib.
RET/NTRK+: Selpercatinib, Larotrectinib.
Immunotherapy Options:

High PD-L1 (≥50%): Pembrolizumab monotherapy.
Low/Negative PD-L1: Pembrolizumab + chemotherapy (carboplatin/pemetrexed or paclitaxel).
Other first-line options:

Atezolizumab + bevacizumab + chemotherapy.
Cemiplimab ± chemo.
Nivolumab + ipilimumab.
Maintenance Therapy:

Pemetrexed, bevacizumab, or continuation of initial targeted therapy after stable disease.
Palliative interventions:

Endobronchial stenting, laser therapy, pleurodesis for symptom control.
Progressive or Recurrent Stage IVB NSCLC
Treatment is personalized based on:

Previous therapy received.
Performance status.
Acquired resistance mutations.
Second-Line Systemic Options:

Docetaxel ± ramucirumab.
Immunotherapy if not previously used (e.g., nivolumab, atezolizumab).
Re-challenge with targeted agents for newly acquired resistance (e.g., EGFR T790M → Osimertinib).
Molecularly driven strategies:

EGFR exon 20 insertions: Amivantamab ± chemo.
ALK progression post-TKI: Brigatinib, Lorlatinib.
ROS1, NTRK, RET, HER2, MET, KRAS G12C: Specific inhibitors in second-line setting.
Other therapies under investigation:

mTOR inhibitors (e.g., Everolimus).
Tumor Treating Fields (TTF) in combination with systemic therapy.
Clinical trials of novel agents, radiosensitizers, adaptive radiation.
Radiation therapy or local ablation for oligoprogressive lesions may be considered in select cases."
SCLC (Small Cell Carcinoma);"T1a; T1b; T1c; T2a; T2b; T2; T3;T4";"N0; N1; N2; N3";M0;LS-SCLC;< 70;"Clinical Stage
TNM Stage: T1–T4, N0–N3, M0 (AJCC 8th Edition) - Satages I; II or III
Classification: Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Disease confined to one hemithorax and regional nodes.
Amenable to treatment within a single, tolerable radiation field.
No evidence of distant metastasis (M0).

Treatment Plan (Guideline-Based)
1. Standard of Care
Concurrent Chemoradiotherapy is the preferred treatment in medically fit patients:
Chemotherapy: Etoposide + cisplatin (or carboplatin) - initial treatment is typically 4 to 6 cycles
Thoracic Radiation Therapy (TRT): Concurrent delivery with chemotherapy
Thoracic radiation therapy (TRT) is commonly delivered either as twice-daily fractions of 1.5 Gy administered every 12 hours for a total dose of 45 Gy over 3 weeks, or as once-daily fractions of 2.0 Gy for a total dose of 66 Gy over approximately 6.5 weeks, with radiation typically initiated during the first or second cycle of chemotherapy.
This combined modality is associated with higher response rates and improved survival versus sequential therapy.
2. Surgical Approach (Selective Use)
Surgical resection (e.g., lobectomy with mediastinal lymph node dissection) may be considered only in very early-stage disease:
Candidates: T1–T2, N0 patients with good cardiopulmonary reserve.
Preoperative staging with mediastinoscopy or EBUS (endobronchial ultrasound) is essential to exclude nodal involvement.
Postoperative management:
Adjuvant chemotherapy (etoposide + platinum)
Thoracic radiation if nodal metastases are confirmed.
3. Alternative Strategy in Medically Ineligible Patients
If the patient cannot tolerate concurrent chemoradiotherapy:
Begin with chemotherapy alone (etoposide + cisplatin/carboplatin)
Sequential TRT may be added if performance status improves or partial response is achieved.
4. Consolidation Immunotherapy (Emerging Option)
For patients who do not progress after concurrent chemoradiotherapy:
Consider durvalumab (anti–PD-L1) as consolidation therapy, based on emerging evidence.

Prophylactic Cranial Irradiation (PCI)
For patients with complete or near-complete response to initial therapy:
PCI significantly reduces risk of brain metastases (from ~60% to <30%)
Radiation regimen: Low-dose whole-brain radiotherapy
Discuss neurocognitive side effects, especially in patients with baseline impairment or age-related vulnerability.
Long-term survivors may experience delayed cognitive decline; follow-up and neurocognitive monitoring are advised.

Clinical Trials
Patients should be evaluated for clinical trial eligibility, especially for:
Novel chemotherapy combinations
New immunotherapy strategies
Optimized radiation schedules (e.g., three-dimensional conformal radiation, adaptive fractionation)

Palliative and Supportive Care
Integrate supportive care early to manage:
Esophagitis, fatigue, neutropenia, and nausea from chemoradiation
Psychological and social impacts
In patients with poor performance status or multiple comorbidities, palliative chemotherapy alone may be considered.

Follow-Up and Surveillance
Imaging:
CT chest every 3–6 months for first 2 years
Brain MRI surveillance if PCI was not administered
Neurocognitive assessment:
Regular testing for patients post-PCI, particularly those >70 years
Symptom monitoring:
Focus on early identification of recurrence or late radiation effects"
SCLC (Small Cell Carcinoma);"T1a; T1b; T1c; T2a; T2b; T2; T3;T4";"N0; N1; N2; N3";M0;LS-SCLC;>= 70;"Clinical Stage
TNM Stage: T1–T4, N0–N3, M0 (AJCC 8th Edition) - Satages I; II or III
Classification: Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Disease confined to one hemithorax and regional nodes.
Amenable to treatment within a single, tolerable radiation field.
No evidence of distant metastasis (M0).

Treatment Plan (Guideline-Based)
1. Standard of Care
Concurrent Chemoradiotherapy is the preferred treatment in medically fit patients:
Chemotherapy: Etoposide + cisplatin (or carboplatin) - initial treatment is typically 4 to 6 cycles
Thoracic Radiation Therapy (TRT): Concurrent delivery with chemotherapy
Thoracic radiation therapy (TRT) is commonly delivered either as twice-daily fractions of 1.5 Gy administered every 12 hours for a total dose of 45 Gy over 3 weeks, or as once-daily fractions of 2.0 Gy for a total dose of 66 Gy over approximately 6.5 weeks, with radiation typically initiated during the first or second cycle of chemotherapy.
This combined modality is associated with higher response rates and improved survival versus sequential therapy.
2. Surgical Approach (Selective Use)
Surgical resection (e.g., lobectomy with mediastinal lymph node dissection) may be considered only in very early-stage disease:
Candidates: T1–T2, N0 patients with good cardiopulmonary reserve.
Preoperative staging with mediastinoscopy or EBUS (endobronchial ultrasound) is essential to exclude nodal involvement.
Postoperative management:
Adjuvant chemotherapy (etoposide + platinum)
Thoracic radiation if nodal metastases are confirmed.
3. Alternative Strategy in Medically Ineligible Patients
If the patient cannot tolerate concurrent chemoradiotherapy:
Begin with chemotherapy alone (etoposide + cisplatin/carboplatin)
Sequential TRT may be added if performance status improves or partial response is achieved.
4. Consolidation Immunotherapy (Emerging Option)
For patients who do not progress after concurrent chemoradiotherapy:
Consider durvalumab (anti–PD-L1) as consolidation therapy, based on emerging evidence.

Prophylactic Cranial Irradiation (PCI)
For patients with complete or near-complete response to initial therapy:
PCI significantly reduces risk of brain metastases (from ~60% to <30%)
Radiation regimen: Low-dose whole-brain radiotherapy
Discuss neurocognitive side effects, especially in patients with baseline impairment or age-related vulnerability.
Long-term survivors may experience delayed cognitive decline; follow-up and neurocognitive monitoring are advised.

Special Considerations: Older Adults (≥70 Years)
Older patients often have:
Lower performance status
More comorbidities
Increased hematological toxicity
Evidence from secondary analyses shows:
Comparable survival outcomes in older vs. younger patients who complete standard therapy
However, treatment-related mortality is significantly higher (e.g., 10% in ≥70 vs. 1% in <70 in EST-3588)
Recommendations:
Carefully evaluate risk–benefit ratio
Consider dose adjustments, use of carboplatin instead of cisplatin, and once-daily TRT
Consider omitting PCI or using MRI surveillance in select frail patients

Clinical Trials
Patients should be evaluated for clinical trial eligibility, especially for:
Novel chemotherapy combinations
New immunotherapy strategies
Optimized radiation schedules (e.g., three-dimensional conformal radiation, adaptive fractionation)

Palliative and Supportive Care
Integrate supportive care early to manage:
Esophagitis, fatigue, neutropenia, and nausea from chemoradiation
Psychological and social impacts
In patients with poor performance status or multiple comorbidities, palliative chemotherapy alone may be considered.

Follow-Up and Surveillance
Imaging:
CT chest every 3–6 months for first 2 years
Brain MRI surveillance if PCI was not administered
Neurocognitive assessment:
Regular testing for patients post-PCI, particularly those >70 years
Symptom monitoring:
Focus on early identification of recurrence or late radiation effects"
SCLC (Small Cell Carcinoma);Any T;Any N;"M1; M1a; M1b; M1c";ES-SCLC;>= 70;"Clinical Stage
TNM Classification: Advanced T/N status with distant metastasis (M1a/M1b/M1c), not confined to a single hemithorax or tolerable radiation field. Stage IV
Staging Classification: Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Evidence-Based Treatment Plan
1. Standard Initial Treatment
First-line therapy for patients with good performance status (ECOG 0–1) includes:
Chemotherapy:
Etoposide + cisplatin or carboplatin -  Cycles are most often 3 or 4 weeks long, and initial treatment is typically 4 to 6 cycles.
Carboplatin preferred in patients with comorbidities (e.g., cardiovascular disease, renal insufficiency) due to lower non-hematologic toxicity
Immunotherapy:
Add a PD-L1 checkpoint inhibitor:
Either Atezolizumab or Durvalumab
Continue the immunotherapy agent as maintenance monotherapy after chemotherapy
This chemo-immunotherapy combination improves overall survival and is now considered standard of care for fit ES-SCLC patients.

2. Radiation Therapy
Radiation is not used upfront due to systemic nature of disease but is applied in specific settings: a. Palliative Radiation:
For symptomatic brain metastases → Whole-brain radiotherapy (WBRT)
For bone, spinal cord, or thoracic involvement causing pain or obstruction (e.g., superior vena cava syndrome) → Site-directed palliative external beam radiation therapy (EBRT)
b. Thoracic Radiation Therapy (TRT):
Can be considered after chemotherapy response in select patients with residual thoracic disease
Shown to improve local control in some studies
c. Prophylactic Cranial Irradiation (PCI):
For patients who respond to initial systemic therapy
Reduces incidence of brain metastases in patients without visible CNS disease
Decision should consider patient age, baseline neurocognitive status, and comorbidity profile

3. Alternative Approaches for Poor Performance Status or Comorbidities
In patients with ECOG ≥2, organ dysfunction, or advanced age:
Consider:
Dose-reduced chemotherapy (e.g., lower dose etoposide + carboplatin)
Single-agent regimens, where indicated
Oral etoposide may be used cautiously, but evidence shows inferior outcomes compared to combination therapy
In frail patients unable to tolerate systemic therapy:
Emphasize palliative/supportive care only
Focus on management of:
Dyspnea
Bone pain
Neurologic symptoms
Psychological distress

4. Special Considerations: Older Adults (≥70 Years)
Toxicity:
Higher rates of myelosuppression and cardiotoxicity
Greater incidence of treatment-related mortality
Treatment Strategy:
Standard first-line chemo-immunotherapy (e.g., etoposide + carboplatin + atezolizumab/durvalumab) may be used in older adults with good performance status (ECOG 0–1) and normal organ function
In frailer older patients:
Use dose modifications, supportive therapies, or palliative-only approaches
Survival:
When fit and appropriately treated, older adults have survival outcomes comparable to younger patients

5. Clinical Trials
Strongly encourage consideration of clinical trial participation, particularly for:
Patients with relapsed/refractory disease
Investigational chemo-immunotherapy combinations
Trials exploring alternative fractionation schedules or targeted agents

6. Palliative and Supportive Care
Integral to management in all ES-SCLC patients
Key elements include:
Symptom control (pain, dyspnea, cough, fatigue)
Management of CNS metastases with WBRT or corticosteroids
Nutritional and psychosocial support
Referral to palliative care teams early in the disease course

7. Follow-Up and Surveillance
After completion of initial treatment:
CT scans every 2–3 months to monitor for recurrence or progression
Brain MRI at intervals if PCI not given
Monitor for:
Chemotherapy-related toxicities (e.g., cytopenias, neuropathy)
Long-term immunotherapy side effects (e.g., pneumonitis, colitis)"
SCLC (Small Cell Carcinoma);Any T;Any N;"M1; M1a; M1b; M1c";ES-SCLC;< 70;"Clinical Stage
TNM Classification: Advanced T/N status with distant metastasis (M1a/M1b/M1c), not confined to a single hemithorax or tolerable radiation field. Stage IV
Staging Classification: Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Evidence-Based Treatment Plan
1. Standard Initial Treatment
First-line therapy for patients with good performance status (ECOG 0–1) includes:
Chemotherapy:
Etoposide + cisplatin or carboplatin -  Cycles are most often 3 or 4 weeks long, and initial treatment is typically 4 to 6 cycles.
Carboplatin preferred in patients with comorbidities (e.g., cardiovascular disease, renal insufficiency) due to lower non-hematologic toxicity
Immunotherapy:
Add a PD-L1 checkpoint inhibitor:
Either Atezolizumab or Durvalumab
Continue the immunotherapy agent as maintenance monotherapy after chemotherapy
This chemo-immunotherapy combination improves overall survival and is now considered standard of care for fit ES-SCLC patients.

2. Radiation Therapy
Radiation is not used upfront due to systemic nature of disease but is applied in specific settings: a. Palliative Radiation:
For symptomatic brain metastases → Whole-brain radiotherapy (WBRT)
For bone, spinal cord, or thoracic involvement causing pain or obstruction (e.g., superior vena cava syndrome) → Site-directed palliative external beam radiation therapy (EBRT)
b. Thoracic Radiation Therapy (TRT):
Can be considered after chemotherapy response in select patients with residual thoracic disease
Shown to improve local control in some studies
c. Prophylactic Cranial Irradiation (PCI):
For patients who respond to initial systemic therapy
Reduces incidence of brain metastases in patients without visible CNS disease
Decision should consider patient age, baseline neurocognitive status, and comorbidity profile

3. Alternative Approaches for Poor Performance Status or Comorbidities
In patients with ECOG ≥2, organ dysfunction, or advanced age:
Consider:
Dose-reduced chemotherapy (e.g., lower dose etoposide + carboplatin)
Single-agent regimens, where indicated
Oral etoposide may be used cautiously, but evidence shows inferior outcomes compared to combination therapy
In frail patients unable to tolerate systemic therapy:
Emphasize palliative/supportive care only
Focus on management of:
Dyspnea
Bone pain
Neurologic symptoms
Psychological distress

4. Clinical Trials
Strongly encourage consideration of clinical trial participation, particularly for:
Patients with relapsed/refractory disease
Investigational chemo-immunotherapy combinations
Trials exploring alternative fractionation schedules or targeted agents

5. Palliative and Supportive Care
Integral to management in all ES-SCLC patients
Key elements include:
Symptom control (pain, dyspnea, cough, fatigue)
Management of CNS metastases with WBRT or corticosteroids
Nutritional and psychosocial support
Referral to palliative care teams early in the disease course

6. Follow-Up and Surveillance
After completion of initial treatment:
CT scans every 2–3 months to monitor for recurrence or progression
Brain MRI at intervals if PCI not given
Monitor for:
Chemotherapy-related toxicities (e.g., cytopenias, neuropathy)
Long-term immunotherapy side effects (e.g., pneumonitis, colitis)"